Second Genome Lands $42,600,000 Series B Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8250f143-34ff-446a-ba2e-a63e29c3509d - Date
4/20/2016 - Company Name
Second Genome - Mailing Address
341 Allerton Avenue South San Francisco, CA 94080 USA - Company Description
Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. - Website
http://www.secondgenome.com - Transaction Type
Venture Equity - Transaction Amount
$42,600,000 - Transaction Round
Series B - Proceeds Purposes
The funds will be used to further expand the Second Genome Microbiome Discovery Platform in a range of indications associated with barrier function, insulin sensitivity, and immune regulation. In addition, proceeds from the financing will be used to advance the clinical investigation of SGM-1019, a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in ulcerative colitis, through human proof-of-concept studies. - M&A Terms
- Venture Investor
Pfizer Venture Investments - Venture Investor
Roche Venture Fund - Venture Investor
Lifeforce Ventures - Venture Investor
Mayo Medical Ventures - Venture Investor
Advanced Technology Ventures - Venture Investor
Morgenthaler Ventures - Venture Investor
Seraph Group - Venture Investor
Investor
